From Paris to the Lab: The Biggest Shifts Shaping Cosmetic Ingredients Right Now

From Paris to the Lab: The Biggest Shifts Shaping Cosmetic Ingredients Right Now

The global cosmetic ingredient landscape is evolving at breakneck speed. From landmark exhibitions to new regulatory opinions and a rising wave of science-driven domestic brands, mid-2026 has already delivered several developments worth tracking. Here is our roundup of the most impactful stories.

1. In-Cosmetics Global 2026 Draws Record Crowds in Paris

The world’s leading personal care ingredients exhibition, In-Cosmetics Global 2026, took place in Paris under the theme “Science at the Core, Beauty Reborn.” With over 1,100 exhibitors and 16,000+ attendees, the event underscored the industry’s accelerating pivot toward evidence-based, sustainability-forward formulation.

Chinese research labs made a strong showing. Betaine Group’s Yunnan Specialty Plant Extraction Lab showcased proprietary highland botanical extracts, signaling growing global recognition of Chinese phytochemistry innovation. The Innovation Zone featured 150+ global ingredient premieres spanning advanced delivery systems, biotech-derived actives, and eco-certified emollients.

2. EU SCCS Releases Final Opinion on CBD in Cosmetics

On April 24, 2026, the European Scientific Committee on Consumer Safety (SCCS) issued its long-awaited final opinion on cannabidiol (CBD) as a cosmetic ingredient. The opinion clarifies maximum safe concentration levels and usage conditions, providing much-needed regulatory clarity for brands operating in the EU market.

This ruling is expected to unlock a wave of CBD-infused skincare and body-care launches across Europe, while also influencing regulatory frameworks in Southeast Asian markets that frequently reference EU standards.

3. ICIC Innovation Conference Highlights Anti-Aging Breakthroughs

The annual International Cosmetic Innovation Conference (ICIC) convened in Shanghai in April 2026, gathering nearly 300 experts across 24 thematic forums with over 3,200 industry professionals. A dominant thread was the convergence of peptide science, exosome research, and advanced delivery vehicles for next-generation anti-aging formulations.

Notably, the conference spotlighted how micro-needle and transdermal delivery technologies—historically confined to clinical aesthetics—are being adapted for at-home skincare, promising deeper penetration of brightening and wrinkle-reduction actives without professional intervention.

4. Bio-Based and Sustainable Raw Materials Gain Serious Traction

Sustainability is no longer optional. Companies like C1Life attracted significant international interest at global exhibitions with bio-based 1,3-propanediol (PDO) and polyhydroxyalkanoates (PHA) derived from non-GMO, non-grain carbon sources. These materials offer biodegradable alternatives to petroleum-derived formulation bases while maintaining performance parity.

With Southeast Asian consumers increasingly demanding clean-beauty certifications, the commercial viability of bio-based emollients, surfactants, and film-formers has reached an inflection point for brands targeting markets like Thailand, Vietnam, and Indonesia.

5. Chinese Brands Surpass 58% Domestic Market Share

According to Euromonitor’s 2025 China beauty industry report, domestic brands now account for over 58% of China’s skincare retail market. The shift is driven by sustained R&D investment and proprietary ingredient development, with leading companies building full-chain capabilities from raw material synthesis to clinical validation.

This trend has implications for the broader Asian market: as Chinese ingredient suppliers mature, their export-ready actives—particularly in the brightening and barrier-repair categories—are expected to reshape ingredient sourcing for Southeast Asian brands seeking high-quality, cost-effective alternatives to Western suppliers.

Looking Ahead

The convergence of stricter regulation, greener chemistry, and deeper scientific rigor is creating a new baseline for cosmetic ingredients. Brands that invest in transparent safety dossiers, sustainable sourcing, and clinically validated actives will be best positioned as these trends accelerate through the second half of 2026 and beyond.